Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Weight loss drugs have 1 big issue
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Popular Weight Loss Drugs Now for Patients With Cancer?
Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.
Compounding group sues FDA for removing Lilly's weight loss drug from shortage list
A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.
Medicare coverage of weight loss drugs would cost $35B: CBO
Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the Congressional Budget Office (CBO). In its estimates released Tuesday, CBO
FDA to review removal of Eli Lilly weight loss drug from shortage list
The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ingredient of Eli Lilly's (NYSE:LLY) diabetes therapy Mounjaro and weight loss therapy Zepbound,
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its shortage list.
3d
on MSN
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...
Science Daily
1d
New drug approach could underpin future weight loss therapies, study indicates
In the research, mice were fed a high-fat diet were injected with the compound AP39, which delivers hydrogen sulfide direct to mitochondria in cells The research concluded that the treatment ...
4d
on MSN
Your employer may start covering weight-loss drugs soon
A growing number of employers are considering covering the blockbuster weight-loss drugs, several surveys show. Workers will ...
2d
Washingtonians share how they afford pricey weight loss medications
Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...
JD Supra
2d
Ozempic Weight Loss Users at Risk of Gastroparesis and Other Stomach Problems, New Study Reveals
A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs ...
4d
Health plans at 1 in 5 large companies cover weight-loss drugs for employees
Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...
1d
Copycat weight loss drugs, Amazon's pharmacies, and CVS vs. Lina Khan: Pharma news roundup
If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...
2d
on MSN
France won’t pay for weight loss drug Wegovy. What about other European countries?
France is the latest European country to refuse to cover weight loss drugs through its national insurance programme. View on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback